NIPA1

Across TCGA pan-cancer cohorts, NIPA1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NIPA1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NIPA1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NIPA1 expression acts as an unfavorable survival marker.

BLCA, CESC, and LUAD are the cancer types where NIPA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.169	0.520	.014	24	view →
CESC	OS	Median	All	0.087	0.587	.001	12	view →
LUAD	OS	Median	All	0.338	0.834	.007	6	view →
SKCM	DFS	Median	All	0.271	0.622	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NIPA1–BLCA (DFS)

Open the BLCA breakdown →